Administration of CTLA4-Ig enhances the incidence of hamster-to-rat xenogeneic bone marrow engraftment and alters the presentation of graft-vs-host disease.
Lee
Y H
YH
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Miki
T
T
Kuddus
R
R
Tandin
A
A
Goller
A L
AL
Subbotin
V
V
Fung
J J
JJ
Peach
R
R
Valdivia
L A
LA
Rao
A S
AS
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology*; D060908:CTLA-4 Antigen; D006224:Cricetinae; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control*; D018796:Immunoconjugates; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D051381:Rats; D011917:Rats, Inbred Lew; D013156:Splenectomy; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology*; D014916:Whole-Body Irradiation
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556708:Ctla4 protein, rat; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000069594:Abatacept